Thymol Derivatives as Antimalarial Agents: Synthesis, Activity Against Plasmodium falciparum, ADMET Profiling, and Molecular Docking Insights
<b>Background:</b> Thymol, a natural phenol with antimicrobial and antioxidant activities, and its derivatives offer promising scaffolds for antimalarial drug development, potentially helping overcome resistance. <b>Materials and Methods:</b> In this study, thymol derivatives were synthesized and assessed as antiplasmodial agents against both resistant and sensitive strains of <i>P. falciparum</i>, as well as <i>Plasmodium knowlesi</i>. The ligand molecules were assessed with <i>Plasmodium falciparum</i> chloroquine resistance transporter (PfCRT)'s potential using in silico molecular docking and ADMET analysis. The parent compound, thymol, was chemically modified through esterification and conjugation with hydroxybenzoic acid and cinnamic acid derivatives to generate analogs with varied substitution patterns. <b>Results:</b> The findings showed that among seven successfully synthesized thymol derivatives, compounds <b>4</b> and <b>6</b> exhibited notable potency against <i>Plasmodium falciparum</i> 3D7 (EC<sub>50</sub> = 6.01 ± 1.7 µM and 6.8 ± 1.1 µM, respectively) with high SI values (16.5 and 14.6, respectively), indicating improved selectivity relative to thymol. The cytotoxicity evaluation against HCF mammalian cells revealed that most thymol derivatives were non-toxic, with CC<sub>50</sub> values greater than 99 µM, except for compound 3 (CC<sub>50</sub> = 71.4 ± 4.5 µM) and compound 1 (CC<sub>50</sub> = 58.4 ± 2.3 µM), which exhibited moderate cytotoxic effects. The molecular docking results showed that compounds <b>3</b> (-8.4 kcal/mol), <b>4</b> (-8.3 kcal/mol), and <b>6</b> (-8.3 kcal/mol) exhibited strong binding affinities toward the PfCRT protein. <b>Conclusions:</b> Therefore, thymol derivative compounds <b>4</b> and <b>6</b> exhibited stronger antiplasmodial activity in vitro against <i>P. falciparum</i> and <i>P. knowlesi</i> with safety profiles against mammalian cells, targeting PfCRT, highlighting their potential as lead antimalarial candidates.
Authors
- Nurhezreen Md Iqbal (ORCID: https://orcid.org/0000-0002-6597-3773)
- Jalifah Latip (ORCID: https://orcid.org/0000-0002-9214-1251)
- Siti Nur Hidayah Jamil (ORCID: https://orcid.org/0000-0002-2815-0663)
- Nabel Darwish Zuhaidi (ORCID: https://orcid.org/0000-0002-5761-763X)
- Sylvia Chieng (ORCID: https://orcid.org/0000-0002-6521-6641)
- Rini Retnosari (ORCID: https://orcid.org/0000-0001-7815-768X)
- Hani Kartini Agustar (ORCID: https://orcid.org/0000-0003-2107-3869)
- Kuhan Chandru (ORCID: https://orcid.org/0000-0002-7438-4831)
- Su Datt Lam
- Nur Aqilah Zahirah Norazmi
- Lau Yee Ling
- Amatul Hamizah Ali
Institutions
- State University of Malang (ID)
- University of Malaya (MY)
- Malaysia Genome Institute (MY)
- Gifu University (JP)
- National University of Malaysia (MY)
Publication Details
- Journal
- Biomedicines
- Published
- 2026-01-08
- DOI
- https://doi.org/10.3390/biomedicines14010123
- Primary Topic
- Malaria Research and Control
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universiti Malaya
- Universiti Kebangsaan Malaysia